Oppenheimer Reiterates Outperform on ArriVent BioPharma, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones has reiterated an Outperform rating on ArriVent BioPharma (NASDAQ:AVBP) and maintained a price target of $35.
August 15, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Jeff Jones has reiterated an Outperform rating on ArriVent BioPharma and maintained a price target of $35.
The reiteration of an Outperform rating and a maintained price target of $35 by a reputable analyst from Oppenheimer is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price of ArriVent BioPharma.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100